1. Badewiijns M.M., van Vlodrop I.J., Vermeulen P.B., Soetekouw P.M., van Engeland M., de Bruine A.P 2010. VHL and HIF signalling in renal cell carcinogenesis. J. Pathol. 221(2), 125–138.
2. Spirina L.V., Kondakova I.V., Usynin E.A., Vintizenko S.I 2008. regulation of angiogenesis in malignant neoplasms of the kidney and urinary bladder. Sib. Onkol. Zh. 4, 65–70.
3. Yurmazov Z.A., Usynin E.A., Spirina L.V., Kondakova I.V., Slonimskaya E.M 2015. Prognostic significance of the expression of transcription factors, VEGF growth factor, its receptor, m-TOR protein kinase, and intracellular proteinase activities in patients with disseminated kidney cancer. Sib. Onkol. Zh. 5, 44–50.
4. Spirina V.L., Usynin E.A., Kondakova I.V., Yurmazov Z.A., Slonimskaya E.M 2015. Molecular markers of kidney cancer progression, association with efficiency of pazopanib therapy. J. Biomed. Sci. Engin. 8, 756–766.
5. Badalian G., Derecskei K., Szendroi A., Szendroi M., Tímár J 2007. EGFR and VEGFR2 protein expressions in bone metastases of clear cell renal cancer. Anticancer Res. 27(2), 889–894.